{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:49:36Z","timestamp":1782107376202,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Vancomycin is used to treat severe infections caused by methicillin-resistant gram-positive bacteria such as methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA). Although several pharmacokinetic studies on vancomycin in burn patients have been reported, a robust population pharmacokinetic model based on routine therapeutic drug monitoring data from a large cohort is still lacking. This study aimed to develop a PopPK model for vancomycin in adult burn patients and evaluate its predictive performance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum vancomycin concentrations from 93 burn patients were analyzed using non-linear mixed-effects modeling. Covariates including age, gender, creatinine clearance (CrCL), BMI, burn cause, and burn area were evaluated using stepwise forward selection and backward elimination. Model stability was assessed by bootstrap. Predictive performance was compared with Clincalc in 9 external burn patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A one-compartment model best described vancomycin PK in burn patients. The final model identified CrCL as a significant covariate on clearance: CL (L\/h) = 6.73 \u00d7 (CrCL\/111.67)\n                      <jats:sup>0.708<\/jats:sup>\n                      , with a volume of distribution of 49.1 L. Bootstrap analysis confirmed good model stability. Our model demonstrated superior predictive accuracy compared with Clincalc.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vancomycin clearance is increased in burn patients and significantly correlated with CrCL. The developed PopPK model provides a reliable basis for individualized vancomycin dosing in this specific population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1829805","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:40:18Z","timestamp":1782106818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Vancomycin population pharmacokinetics in patients with burns"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Burn, Shanghai Burn Institute, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University","place":["Shanghai, China"]},{"name":"Department of Pharmacy, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunben","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital, Xinjiang Medical University","place":["\u00dcr\u00fcmqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Burn, Shanghai Burn Institute, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1089\/sur.2020.346","article-title":"Burn wound colonization, infection, and sepsis.","volume":"22","author":"Ladhani","year":"2021","journal-title":"Surg Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.burns.2020.05.004","article-title":"Bacterial infection profile and predictors among patients admitted to a burn care center: a retrospective study.","volume":"46","author":"Bourgi","year":"2020","journal-title":"Burns."},{"key":"B3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/sur.2020.104","article-title":"Novel therapeutics for the treatment of burn infection.","volume":"22","author":"Salyer","year":"2021","journal-title":"Surg Infect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.burns.2021.03.004","article-title":"Early protein C activation is reflective of burn injury severity and plays a critical role in inflammatory burden and patient outcomes.","volume":"48","author":"Zhao","year":"2022","journal-title":"Burns."},{"key":"B5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/FTD.0000000000001067","article-title":"Optimization of antimicrobial stewardship programs using therapeutic drug monitoring and pharmacokinetics-pharmacodynamics protocols: a cost-benefit review.","volume":"45","author":"Telles","year":"2023","journal-title":"Ther Drug Monit."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus.","volume":"124","author":"Gardete","year":"2014","journal-title":"J Clin Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FTD.0000000000000944","article-title":"Optimal practice for vancomycin therapeutic drug monitoring: position statement from the anti-infectives committee of the international association of therapeutic drug monitoring and clinical toxicology.","volume":"44","author":"Reuter","year":"2022","journal-title":"Ther Drug Monit."},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","article-title":"Therapeutic drug monitoring of antibiotics: defining the therapeutic range.","volume":"44","author":"Abdul-Aziz","year":"2022","journal-title":"Ther Drug Monit."},{"key":"B9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/FTD.0000000000000622","article-title":"Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections.","volume":"41","author":"Clark","year":"2019","journal-title":"Ther Drug Monit."},{"key":"B10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/FTD.0000000000000801","article-title":"Population pharmacokinetic modeling of vancomycin in thai patients with heterogeneous and unstable renal function.","volume":"42","author":"Jaisue","year":"2020","journal-title":"Ther Drug Monit."},{"key":"B11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/FTD.0000000000000978","article-title":"Association of vancomycin trough concentration and clearance with febrile neutropenia in pediatric patients.","volume":"44","author":"Amano","year":"2022","journal-title":"Ther Drug Monit."},{"key":"B12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/clpt.1986.111","article-title":"Vancomycin elimination in patients with burn injury.","volume":"39","author":"Brater","year":"1986","journal-title":"Clin Pharmacol Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/AAC.34.5.792","article-title":"Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.","volume":"34","author":"Rybak","year":"1990","journal-title":"Antimicrob Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/0310057X1404200203","article-title":"Estimation of glomerular filtration rate to adjust vancomycin dosage in critically ill patients: superiority of the Chronic Kidney Disease Epidemiology Collaboration equation?","volume":"42","author":"Conil","year":"2014","journal-title":"Anaesth Intensive Care."},{"key":"B15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.burns.2017.10.004","article-title":"Characterization of variables for potential impact on vancomycin pharmacokinetics in thermal or inhalation injury.","volume":"44","author":"Elder","year":"2018","journal-title":"Burns."},{"key":"B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"B17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.burns.2009.08.010","article-title":"Vancomycin pharmacokinetics in patients with severe burn injuries.","volume":"36","author":"Dolton","year":"2010","journal-title":"Burns."},{"key":"B18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.burns.2010.06.005","article-title":"Optimizing initial vancomycin dosing in burn patients.","volume":"37","author":"Elligsen","year":"2011","journal-title":"Burns."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1097\/BCR.0b013e31825042fa","article-title":"Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy.","volume":"33","author":"Akers","year":"2012","journal-title":"J Burn Care Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/j.1552-4604.1986.tb02923.x","article-title":"Postburn serum drug binding and serum protein concentrations.","volume":"26","author":"Bloedow","year":"1986","journal-title":"J Clin Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/08971900211012395","article-title":"Assessment of the Implementation of AUC Dosing and Monitoring Practices With Vancomycin at Hospitals Across the United States.","volume":"35","author":"Bradley","year":"2022","journal-title":"J Pharm Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","article-title":"Readiness to implement vancomycin monitoring based on area under the concentration-time curve: a cross-sectional survey of a national health consortium.","volume":"76","author":"Kufel","year":"2019","journal-title":"Am J Health Syst Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/cts.13210","article-title":"Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: pharmacokinetic model and model-informed precision dosing trial simulations.","volume":"15","author":"Aljutayli","year":"2022","journal-title":"Clin Transl Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/clpt.1988.105","article-title":"Altered vancomycin dose vs. serum concentration relationship in burn patients.","volume":"44","author":"Garrelts","year":"1988","journal-title":"Clin Pharmacol Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1128\/AAC.22.3.391","article-title":"Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.","volume":"22","author":"Rotschafer","year":"1982","journal-title":"Antimicrob Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/jac\/dkv372","article-title":"Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.","volume":"71","author":"Medell\u00edn-Garibay","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/j.1582-4934.2009.00644.x","article-title":"Calcium and ER stress mediate hepatic apoptosis after burn injury.","volume":"13","author":"Jeschke","year":"2009","journal-title":"J Cell Mol Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.burns.2008.05.016","article-title":"Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.","volume":"35","author":"Yang","year":"2009","journal-title":"Burns."},{"key":"B29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00004630-198909000-00010","article-title":"The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries.","volume":"10","author":"Zokufa","year":"1989","journal-title":"J Burn Care Rehabil."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:40:19Z","timestamp":1782106819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":29,"alternative-id":["10.3389\/fmed.2026.1829805"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1829805","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1829805"}}